Testing and disclosures related to amyloid imaging and Alzheimer's disease: Common questions and fact sheet summary

Gil D. Rabinovici, Jason Karlawish, David S Knopman, Heather M. Snyder, Reisa Sperling, Maria C. Carrillo

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Alzheimer's disease research has often focused on the molecular brain changes that promote memory loss and other dementia-related cognitive impairments. Many studies, for example, have used positron emission tomography (PET) imaging to measure brain levels of the beta-amyloid protein, a key molecular suspect in Alzheimer's. In recent years, PET scans have become more prominent in clinical settings. Clinicians may use a positive PET scan - that is, a significant presence of beta-amyloid plaques in the brain - to help determine a diagnosis of Alzheimer's disease. Yet, because beta-amyloid PET remains a fairly new diagnostic tool, physicians and patients still have many basic questions about how and why it is used. This article addresses some of those questions. It explains what PET scans actually show, how they are employed in research and clinical trials, and when they should and should not be used to help diagnose Alzheimer's in everyday patients. The article also discusses whether cognitively healthy people should request PET scans to assess their risk for developing dementia. Information in the text will be updated in future years, as diagnostic imaging techniques for Alzheimer's disease continue to evolve.

Original languageEnglish (US)
Pages (from-to)510-515
Number of pages6
JournalAlzheimer's and Dementia
Volume12
Issue number4
DOIs
StatePublished - Apr 1 2016

Fingerprint

Disclosure
Amyloid
Positron-Emission Tomography
Alzheimer Disease
Dementia
Brain
Amyloid beta-Peptides
Amyloid Plaques
Memory Disorders
Diagnostic Imaging
Research
Clinical Trials
Physicians

Keywords

  • Alzheimer's Association
  • Alzheimer's disease
  • Amyloid Imaging Taskforce (AIT)
  • Appropriate use criteria (AUC)
  • Beta-amyloid
  • Cortex
  • Dementia
  • Magnetic resonance imaging (MRI)
  • Mild cognitive impairment (MCI)
  • National Institute on Aging (NIA)
  • National Institutes of Health (NIH)
  • Plaques
  • Positron emission tomography (PET)
  • Tau tangles

ASJC Scopus subject areas

  • Clinical Neurology
  • Developmental Neuroscience
  • Cellular and Molecular Neuroscience
  • Psychiatry and Mental health
  • Geriatrics and Gerontology
  • Epidemiology
  • Health Policy

Cite this

Testing and disclosures related to amyloid imaging and Alzheimer's disease : Common questions and fact sheet summary. / Rabinovici, Gil D.; Karlawish, Jason; Knopman, David S; Snyder, Heather M.; Sperling, Reisa; Carrillo, Maria C.

In: Alzheimer's and Dementia, Vol. 12, No. 4, 01.04.2016, p. 510-515.

Research output: Contribution to journalArticle

Rabinovici, Gil D. ; Karlawish, Jason ; Knopman, David S ; Snyder, Heather M. ; Sperling, Reisa ; Carrillo, Maria C. / Testing and disclosures related to amyloid imaging and Alzheimer's disease : Common questions and fact sheet summary. In: Alzheimer's and Dementia. 2016 ; Vol. 12, No. 4. pp. 510-515.
@article{531fbe9006d94dcda9ae19a4774a720c,
title = "Testing and disclosures related to amyloid imaging and Alzheimer's disease: Common questions and fact sheet summary",
abstract = "Alzheimer's disease research has often focused on the molecular brain changes that promote memory loss and other dementia-related cognitive impairments. Many studies, for example, have used positron emission tomography (PET) imaging to measure brain levels of the beta-amyloid protein, a key molecular suspect in Alzheimer's. In recent years, PET scans have become more prominent in clinical settings. Clinicians may use a positive PET scan - that is, a significant presence of beta-amyloid plaques in the brain - to help determine a diagnosis of Alzheimer's disease. Yet, because beta-amyloid PET remains a fairly new diagnostic tool, physicians and patients still have many basic questions about how and why it is used. This article addresses some of those questions. It explains what PET scans actually show, how they are employed in research and clinical trials, and when they should and should not be used to help diagnose Alzheimer's in everyday patients. The article also discusses whether cognitively healthy people should request PET scans to assess their risk for developing dementia. Information in the text will be updated in future years, as diagnostic imaging techniques for Alzheimer's disease continue to evolve.",
keywords = "Alzheimer's Association, Alzheimer's disease, Amyloid Imaging Taskforce (AIT), Appropriate use criteria (AUC), Beta-amyloid, Cortex, Dementia, Magnetic resonance imaging (MRI), Mild cognitive impairment (MCI), National Institute on Aging (NIA), National Institutes of Health (NIH), Plaques, Positron emission tomography (PET), Tau tangles",
author = "Rabinovici, {Gil D.} and Jason Karlawish and Knopman, {David S} and Snyder, {Heather M.} and Reisa Sperling and Carrillo, {Maria C.}",
year = "2016",
month = "4",
day = "1",
doi = "10.1016/j.jalz.2016.03.002",
language = "English (US)",
volume = "12",
pages = "510--515",
journal = "Alzheimer's and Dementia",
issn = "1552-5260",
publisher = "Elsevier Inc.",
number = "4",

}

TY - JOUR

T1 - Testing and disclosures related to amyloid imaging and Alzheimer's disease

T2 - Common questions and fact sheet summary

AU - Rabinovici, Gil D.

AU - Karlawish, Jason

AU - Knopman, David S

AU - Snyder, Heather M.

AU - Sperling, Reisa

AU - Carrillo, Maria C.

PY - 2016/4/1

Y1 - 2016/4/1

N2 - Alzheimer's disease research has often focused on the molecular brain changes that promote memory loss and other dementia-related cognitive impairments. Many studies, for example, have used positron emission tomography (PET) imaging to measure brain levels of the beta-amyloid protein, a key molecular suspect in Alzheimer's. In recent years, PET scans have become more prominent in clinical settings. Clinicians may use a positive PET scan - that is, a significant presence of beta-amyloid plaques in the brain - to help determine a diagnosis of Alzheimer's disease. Yet, because beta-amyloid PET remains a fairly new diagnostic tool, physicians and patients still have many basic questions about how and why it is used. This article addresses some of those questions. It explains what PET scans actually show, how they are employed in research and clinical trials, and when they should and should not be used to help diagnose Alzheimer's in everyday patients. The article also discusses whether cognitively healthy people should request PET scans to assess their risk for developing dementia. Information in the text will be updated in future years, as diagnostic imaging techniques for Alzheimer's disease continue to evolve.

AB - Alzheimer's disease research has often focused on the molecular brain changes that promote memory loss and other dementia-related cognitive impairments. Many studies, for example, have used positron emission tomography (PET) imaging to measure brain levels of the beta-amyloid protein, a key molecular suspect in Alzheimer's. In recent years, PET scans have become more prominent in clinical settings. Clinicians may use a positive PET scan - that is, a significant presence of beta-amyloid plaques in the brain - to help determine a diagnosis of Alzheimer's disease. Yet, because beta-amyloid PET remains a fairly new diagnostic tool, physicians and patients still have many basic questions about how and why it is used. This article addresses some of those questions. It explains what PET scans actually show, how they are employed in research and clinical trials, and when they should and should not be used to help diagnose Alzheimer's in everyday patients. The article also discusses whether cognitively healthy people should request PET scans to assess their risk for developing dementia. Information in the text will be updated in future years, as diagnostic imaging techniques for Alzheimer's disease continue to evolve.

KW - Alzheimer's Association

KW - Alzheimer's disease

KW - Amyloid Imaging Taskforce (AIT)

KW - Appropriate use criteria (AUC)

KW - Beta-amyloid

KW - Cortex

KW - Dementia

KW - Magnetic resonance imaging (MRI)

KW - Mild cognitive impairment (MCI)

KW - National Institute on Aging (NIA)

KW - National Institutes of Health (NIH)

KW - Plaques

KW - Positron emission tomography (PET)

KW - Tau tangles

UR - http://www.scopus.com/inward/record.url?scp=84963955078&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84963955078&partnerID=8YFLogxK

U2 - 10.1016/j.jalz.2016.03.002

DO - 10.1016/j.jalz.2016.03.002

M3 - Article

C2 - 27103054

AN - SCOPUS:84963955078

VL - 12

SP - 510

EP - 515

JO - Alzheimer's and Dementia

JF - Alzheimer's and Dementia

SN - 1552-5260

IS - 4

ER -